Modest Activity of Pomalidomide in Patients with Myelofibrosis and Significant Anemia

We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5mg/day continuously. Three patients (10%...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Leuk Res
Hoofdauteurs: Daver, Naval, Shastri, Aditi, Kadia, Tapan, Quintas-Cardama, Alfonso, Jabbour, Elias, Konopleva, Marina, O’Brien, Susan, Pierce, Sherry, Zhou, Lingsha, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2013
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4232180/
https://ncbi.nlm.nih.gov/pubmed/23890523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2013.07.007
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items